DOC-1021
- Generic Name
- DOC-1021
Dendritic Cell Immunotherapy for Treatment of Adult GBM
Phase 2
Recruiting
- Conditions
- Glioblastoma (GBM)
- Interventions
- Procedure: Tumor resectionRadiation: SOC cranial radiation
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Diakonos Oncology Corporation
- Target Recruit Count
- 135
- Registration Number
- NCT06805305
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath